Published in
American Society for Microbiology, Antimicrobial Agents and Chemotherapy, 5(65), 2021
DOI: 10.1128/aac.01553-20
Links
Tools
Novel Short-Course Therapy and Morphism Mapping for Clinical Pulmonary Mycobacterium kansasii
Journal article published in 2021 by
Shashikant Srivastava 
,
Jann-Yuan Wang ,
Gesham Magombedze,
Moti Chapagain,
Hung-Ling Huang,
Devyani Deshpande,
Scott K. Heysell,
Jotam G. Pasipanodya,
Tawanda Gumbo
,
Jann-Yuan Wang ,
Gesham Magombedze,
Moti Chapagain,
Hung-Ling Huang,
Devyani Deshpande,
Scott K. Heysell,
Jotam G. Pasipanodya,
Tawanda Gumbo
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Data provided by 
Abstract
Standard therapy (isoniazid, rifampin, and ethambutol), with or without a macrolide, for pulmonary Mycobacterium kansasii lasts more than a year. Therefore, shorter treatment duration regimens are required.